Global Cancer Stem Cell Therapy Market - 2024-2031

Global Cancer Stem Cell Therapy Market - 2024-2031

Global Cancer Stem Cell Therapy Market reached US$ YY million in 2023 and is expected to reach US$ YY million by 2031, growing at a CAGR of YY% during the forecast period 2024-2031.

Stem cell therapy is a regenerative medicine that repairs damaged cells by reducing inflammation and modulating the immune system, making it a viable treatment option for various medical conditions. Stem cell transplantation is a cancer treatment that restores stem cells responsible for blood-forming in patients who have had their blood-forming stem cells destroyed through radiotherapy or chemotherapy.

This treatment is used to treat leukaemia, lymphoma, neuroblastoma, and multiple myeloma. In a stem cell transplant, the patient receives healthy blood-forming stem cells through a vein, which travel to the bone marrow to replace the cells destroyed by treatment. Transplants can be autologous, allogeneic, or syngeneic.

Market Dynamics: Drivers & Restraints

Rise in the prevalence of cancer cases

The global increase in cancer cases due to efficient disease treatment is driving demand for the cancer stem cells market. Cancer stem cell therapy targets specific cancer cells to eliminate post-treatment cancer. It involves intricate processes like genetic modulation, cell isolation, and personalized treatment planning. These factors collectively contribute to the growth of the cancer stem cell market.

For instance, each year, the American Cancer Society estimates the number of new cancer cases and deaths in the United States and compiles the most recent data on population-based cancer occurrence and outcomes using incidence data collected by central cancer registries and mortality data collected by the National Center for Health Statistics. In 2023, 1,958,310 new cancer cases and 609,820 cancer deaths are projected to occur in the United States.



High costs associated with the treatment

Cancer stem cell therapy development necessitates extensive research, clinical trials, and preclinical investigations, resulting in high costs and increased expenditure. This leads to a higher retail price of the drug upon approval, limiting the growth of the cancer stem cell market. The high cost of cancer treatment is a significant barrier to its development.



For more details on this report – Request for Sample

Segment Analysis

The global cancer stem cell therapy market is segmented based on therapy type, cancer type end-user and region.

The autologous stem cell transplants from the therapy type segment accounted for approximately 52.3% of the cancer stem cell therapy market share

The autologous stem cell transplants from the therapy type segment accounted for approximately 42.3%. Autologous stem cell transplants are typically used in people who need to undergo high doses of chemotherapy and radiation to cure their diseases. These treatments are likely to damage the bone marrow. An autologous stem cell transplant helps to replace the damaged bone marrow.

For instance, in September 2023, BioLineRx Ltd. a commercial-stage biopharmaceutical company focused on certain cancers and rare diseases, announced that the U.S. Food and Drug Administration (FDA) has approved APHEXDA (motixafortide) in combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma. APHEXDA is administered by injection, for subcutaneous use.

Geographical Analysis

North America is estimated to hold about 43.4% of the total market share throughout the forecast period

North America is estimated to hold about 38.4% of the total market share throughout the forecast period owing to factors like the established healthcare sector, developed economies like the US and Canada investing in chronic disease treatment, and the presence of major pharmaceutical companies and research centers. Also, technologically advanced healthcare infrastructure and biomedical research centers are actively researching various cancer treatment methods, contributing to the market's growth.

For instance, in March 2024, Stanford Medicine became the first center in the nation to treat a patient with metastatic melanoma using a new cell-based therapy approved by the Food and Drug Administration. The therapy, which offers hope for people with advanced melanoma whose cancers have resisted immunotherapies, is the first cell-based therapy approved by the FDA to treat solid tumors.

Covid 19 Impact Analysis

The COVID-19 pandemic significantly impacted the market, leading to increased focus on healthcare and biomedical research. Funding agencies and governments allocated resources for research, including cancer stem cell therapy. The pandemic also prompted researchers to adapt and innovate, resulting in new strategies and collaborations.

Market Segmentation

By Product Type
• Autologous Stem Cell Transplants
• Allogeneic Stem Cell Transplants
• Syngeneic Stem Cell Transplants
• Others

By Cancer Type
• Breast Cancer
• Bladder Cancer
• Blood Cancer
• Lung Cancer
• Brain Cancer
• Others

By End User
• Hospitals
• Clinics
• Academic and Research Institutes
• Others

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
UK
France
Italy
Spain
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in the market include Thermo Fisher Scientific, Inc., Advanced Cell Diagnostics, Silicon Biosystems, Celularity Inc., Gamida Cell Ltd, Sumitomo Dainippon Pharma Co. Ltd, Merck KGaA, Genentech Inc., Astellas Pharma Inc., Novadip Biosciences among others.

Key Developments

 In February 2024, Thumbay University Hospital launched the Cancer Center at Thumbay University in Al Jurf, Ajman. The fully equipped centre will be active by the end of February 2024. The rising demand for cancer treatment and screening in the Northern Emirates resulted in the launch of these centres. The cancer centre will offer affordable cancer care focusing on multidisciplinary treatment.

 In January 2024, Glenmark Pharma, in collaboration with Ichnos Science, announced the Ichnos Glenmark Innovation (IGI) to increase drug delivery in cancer treatment.



Why Purchase the Report??
• To visualize the global cancer stem cell therapy market segmentation based on therapy type, cancer type, end user and region as well as understand key commercial assets and players.
• identify commercial opportunities by analyzing trends and co-development.
• excel data sheet with numerous data points of the cancer stem cell therapy market level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global cancer stem cell therapy market report would provide approximately 64 tables, 61 figures and 186 pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies